spacer
home > pmps > autumn 2017 > looking after little ones
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Looking After Little Ones

As physicians become more reliant on prescribing medications to treat illness instead of advocating preventive measures, the risks associated with accidental medication poisonings is increasing. In the UK, approximately 50% of the population take prescription medicine, while in the US the figure is over 60% (1-2). These figures are not quoted to reflect in any way on cases genuinely requiring prescription medication. However, they do provide an insight into the volume of drugs in circulation and, with this, the scale of potential risk to children. Poison centres in the US treat 60,000-70,000 children each year for accidental ingestion.

Advancements in packaging technology, such as soluble packs, films and more, are undoubtedly to be viewed as progress. Despite this, it is questionable whether there is a parallel effort in creating the child-resistant packaging necessary to ensure these products are safe for the environments they occupy. While Mercola reports that pain medications are the single most frequent cause of fatalities from accidental medication poisonings in children, household products still present an alarming number of ingestion cases (3). In terms of medicine, the category of substances with the largest number of deaths across all ages including intentional use of opioids in teens are medications containing acetaminophen, sedatives, sleeping medications, stimulants and cardiovascular drugs. In regard to household products, the most common issue is becoming the soluble-packed alkaline detergents.

An abundance of information and creative solutions are available to the packaging industry. With the ease-of-access to online resources, manufacturers are able to appraise themselves in consumer and regulatory concerns, and safety is no exception. However, there is possibly a lack of understanding as to what truly constitutes child-resistant packaging, as well as a preparedness to await regulatory obligation before introducing protection.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Quelch attended The University of Hull, UK, where he studied marketing and advertising. He went on to work across many large marketing agencies, supporting brand packaging developments. Richard joined Origin Pharma Packaging in 2015, strategically working on the brand to position the company in its rightful place: providing excellence in child-resistant packaging for the pharma industry. He aspires to educate the industry and ensure it is driving its ethical duty to protect children. Over the past two years, the organisation has become a thought leader in innovations for child-resistant packaging and continues to work with pharma manufacturers and contract manufacturing organisations across the globe in creating compliant child-resistant packaging and ensuring the safety of children in domestic environments.
spacer
Richard Quelch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI and CSP Technologies, Inc. Announce Strategic Collaboration for Breakthrough Activ-BlisterTM Solutions

Philadelphia, PA & Auburn, AL September 17, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce its exclusive collaboration agreement with CSP Technologies, Inc. for U.S. clinical trials and stability testing utilizing Activ-BlisterTM packaging solutions, which help protect and promote speed-to-market for pharmaceutical and medical device products with heightened susceptibility to moisture and gases, especially oxygen.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018, Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement